source
- Roche touts strong Phase 3 track record while trimming pipeline amid peer setbacksRoche's chief executive Thomas Schinecker highlighted the company's high success rate in Phase 3 trials, positioning it as a competitive advantage. The comment accompanied an announcement that Roc…
- FDA issues warning letters to Baxter and Olympus over GMP and QSR violationsThe U.S. Food and Drug Administration sent formal warning letters to Baxter International and Olympus Medical Systems. The letters allege that both companies failed to meet required good manufactu…